Breaking News

Omeros Expands License of PDE7 Inhibitors

Omeros Corp. has expanded its exclusive license of phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd. to include addiction and compulsive disorders.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Omeros Corp. has expanded its exclusive license of phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd. to include addiction and compulsive disorders. Omeros believes that PDE7 inhibitors could be effective therapeutics for the treatment of movement disorders, such as Parkinson’s disease, as well as addiction and compulsive disorders. Omeros has shown in animal models of cocaine addiction that PDE7 inhibitors reduce cocaine self-administration, inhibit relapse induced by cues ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters